CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Novo Nordisk says compounded drugs are hurting Wegovy sales Cagrilintide New Rx? (Obesity Doctor) 1 CagriSema 2.4 mg 2.4 mg FDA NDA filing; Novo Nordisk data on file., 2 Garvey WT, Blher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors Acta Pharmacologica Sinica Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors Nature Communications